BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
about
How I report breast magnetic resonance imaging studies for breast cancer staging and screeningMRI screening for breast cancer in women at high risk; is the Australian breast MRI screening access program addressing the needs of women at high risk of breast cancer?Breast cancer screening: an evidence-based updateIntensified surveillance for early detection of breast cancer in high-risk patientsContribution of mammography to MRI screening in BRCA mutation carriers by BRCA status and age: individual patient data meta-analysisGenetic risk assessments in individuals at high risk for inherited breast cancer in the breast oncology care setting.Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density.Clinical management of hereditary breast cancer syndromes.Cost-effectiveness of alternative strategies for integrating MRI into breast cancer screening for women at high risk.Breast density as indicator for the use of mammography or MRI to screen women with familial risk for breast cancer (FaMRIsc): a multicentre randomized controlled trial.The risk of primary and contralateral breast cancer after ovarian cancer in BRCA1/BRCA2 mutation carriers: Implications for counseling.Substantial breast cancer risk reduction and potential survival benefit after bilateral mastectomy when compared with surveillance in healthy BRCA1 and BRCA2 mutation carriers: a prospective analysis.Worse breast cancer prognosis of BRCA1/BRCA2 mutation carriers: what's the evidence? A systematic review with meta-analysis.Discrimination of benign and malignant breast lesions by using shutter-speed dynamic contrast-enhanced MR imaging.Repeated nipple fluid aspiration: compliance and feasibility results from a prospective multicenter studyClinical Considerations of BRCA1- and BRCA2-Mutation Carriers: A Review.Long-term results of screening with magnetic resonance imaging in women with BRCA mutations.The relationship of breast density in mammography and magnetic resonance imaging in high-risk women and women with breast cancerCost-effectiveness of alternating magnetic resonance imaging and digital mammography screening in BRCA1 and BRCA2 gene mutation carriersBreast Cancer Screening for High-Risk Patients of Different Ages and Risk - Which Modality Is Most Effective?Secretome proteomics reveals candidate non-invasive biomarkers of BRCA1 deficiency in breast cancer.Screening with magnetic resonance imaging, mammography and ultrasound in women at average and intermediate risk of breast cancer.The current status of positron emission mammography in breast cancer diagnosis.BRCA1 and BRCA2 - update and implications on the genetics of breast cancer: a clinical perspective.Li-Fraumeni syndrome: cancer risk assessment and clinical management.The additional cancer yield of clinical breast examination in screening of women at hereditary increased risk of breast cancer: a systematic review.The role of dynamic contrast-enhanced screening breast MRI in populations at increased risk for breast cancer.The impact of oophorectomy on survival after breast cancer in BRCA1-positive breast cancer patients.Screening Breast MRI Outcomes in Routine Clinical Practice: Comparison to BI-RADS Benchmarks.Breast cancer screening: a 35-year perspective.Should we screen BRCA1 mutation carriers only with MRI? A multicenter study.Breast cancer detection and tumor characteristics in BRCA1 and BRCA2 mutation carriers.Breast fine-needle aspiration cytology performance in the high-risk screening population: a study of BRCA1/BRCA2 mutation carriers.MRI breast screening in high-risk women: cancer detection and survival analysis.Quality-of-life implications of risk-reducing cancer surgery.Advanced Imaging for Precision Medicine in Breast Cancer: From Morphology to Function.Cost-effectiveness and comparative effectiveness of cancer risk management strategies in BRCA1/2 mutation carriers: a systematic review.Hereditary breast and ovarian cancer and reproduction: an observational study on the suitability of preimplantation genetic diagnosis for both asymptomatic carriers and breast cancer survivors.Survival of patients with BRCA1-associated breast cancer diagnosed in an MRI-based surveillance program.Relevance and efficacy of breast cancer screening in BRCA1 and BRCA2 mutation carriers above 60 years: a national cohort study.
P2860
Q26741706-69E4EB8B-816A-4B63-9B4A-583A431F6366Q26785571-6BCADF1A-0776-44FF-9E4D-58906FAF4902Q28081267-3A45DCF4-5FC5-4E26-81EF-ECE535A1BB44Q30392157-CBB6C506-82C3-4AD6-8A46-EDA443D1B398Q31048641-45BCD325-9426-4E2D-BD8C-7EDF49DA3B4FQ33564013-D170888E-27C8-450D-A04B-C277A1FFE65BQ33926477-7B1E0167-332F-4F21-856F-0D662922CF0CQ34167563-82F34BAD-42F1-4785-8359-70ADC89EA1D9Q34354614-820C7122-C25D-4830-9888-B6B3DB82ADD5Q34432389-8D9015AF-90C5-4FD7-9902-D66A688B1369Q34481713-9BF9759A-929F-45B5-935C-4303A6E3911EQ34663394-248210D8-3D56-4E40-8C84-CC08313AEC16Q35224593-51037D06-64FB-47F1-A4EF-6E25E2900A91Q35407336-DC3D6D01-1810-4C1D-9CDC-71B8AECECB36Q35637243-99A49FBF-3BFC-4473-94C4-21662DCD99E4Q35687632-15823F17-A34F-423F-A8F6-313D9E1CB79EQ36075216-FF18F348-8C53-46B0-B35D-6C2190209A6DQ36391200-02950292-3812-4001-98A4-E676996ACBA0Q36652732-0D9D9BB5-2291-4E21-97F7-0CF41299E168Q37608651-A92E8781-99FC-4DCF-93F3-8913BDB7E409Q37665387-ADFC91E1-E87A-4C79-93A6-5C3F16B05D27Q37676814-73C8D571-D0C2-422F-8000-922B9B7C7CC1Q38067336-D33B0A0D-CB31-43C8-B108-16AB19B4AFABQ38151730-B671FBD8-731F-426A-8DF8-C1BD9155C393Q38197030-B11BF4FB-2BE2-4F2B-80A0-DED1E8FE4C3BQ38238014-AD48156F-2A4D-40D1-8A6E-E094663D635BQ38284365-52F42E34-4E0C-48B6-B75A-118D93F5ECEEQ38777240-B15AB256-9A58-4C44-96CD-F07E629392C5Q39041817-575C99AC-82ED-49EA-88D3-E45DA9652230Q39736619-4A70A5D2-6866-4032-A55D-12E53FDB8F63Q40173313-DDF088C9-BABE-4EF0-BE2B-5705DDBD321BQ40273462-2D4AFDF2-2BF5-4CDA-B586-1D9B46B5014AQ43639185-1089C945-F3AE-4D75-A62F-D1E5FE1A6113Q45243016-67798AEE-F16E-4F4F-8A74-ACEB7462EF56Q48229444-83CD341B-4750-48CB-B00F-EF1D66D45EA7Q50085553-D47BC7D5-0D92-491A-8CAA-98462315C01DQ50091589-6484AF58-F989-4CE1-B0C0-AAAF918CCED8Q51145030-110B5820-58AD-4F15-AC90-A59107C031D4Q51212622-C2A97216-AC32-4E16-8A46-A4694879FF2CQ51245901-7E264494-2E0B-43C1-98AC-D9A6F02CF81D
P2860
BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: long-term follow-up of the Dutch MRISC Screening Study.
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@ast
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@en
type
label
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@ast
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@en
prefLabel
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@ast
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@en
P2093
P50
P356
P1476
BRCA1-associated breast cancer ...... e Dutch MRISC Screening Study.
@en
P2093
Adriana J Rijnsburger
Carina C M Bartels
Carla Boetes
Claudette E Loo
Elisabeth Bergers
Emiel J T Rutgers
Hans Peterse
Harry J de Koning
Inge-Marie Obdeijn
Jan C Oosterwijk
P304
P356
10.1200/JCO.2009.27.2294
P407
P577
2010-11-15T00:00:00Z